PPARγ as a new therapeutic target in inflammatory bowel diseases

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist2002 · 548 citations
2. 2Differential induction of PPAR-γ by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel2005 · 68 citations
3. 3Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease2005 · 317 citations
4. 4Series Introduction: COX in a crystal ball: current status and future promise of prostaglandin research2001 · 46 citations
5. 5Pioglitazone, a PPAR-γ ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-κB-cytokine cascade2002 · 64 citations